Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells
- 1 June 2016
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 376 (1) , 118-126
Abstract
No abstract availableKeywords
Funding Information
- University of Toledo (F110760)
- Tuskegee RCMI Core (G12MD007585-23)
- IBS-REU program and MSM/TU/UAB Comprehensive Cancer Center Partnership [NCI] (U54 CA118623)
- Auburn University (101069-139268-2052)
- Animal Health and Disease Research (101002-139268-2055)
This publication has 33 references indexed in Scilit:
- Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft modelsCancer Letters, 2013
- Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic responseCancer Letters, 2013
- Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transportAmerican Journal of Physiology-Cell Physiology, 2010
- The Human Breast Cancer Resistance Protein (BCRP/ABCG2) Shows Conformational Changes with MitoxantroneStructure, 2010
- Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug BindingScience, 2009
- The Role of ATP Binding Cassette Transporters in Tissue Defense and Organ RegenerationThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Substrate recognition and transport by multidrug resistance protein 1 (ABCC1)FEBS Letters, 2005
- Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectantsInternational Journal of Cancer, 2003
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002